Biofrontera Celebrates Successful Completion of Study
Biofrontera Inc. has reached an important milestone with the completion of its Phase 1 study on Ameluz®, a pivotal moment for the biopharmaceutical company's growth and its commitment to addressing dermatological conditions.
Understanding the Phase 1 Study
The recently concluded Maximal-use Phase 1 study meticulously evaluated the pharmacokinetic (PK) profile following the application of Ameluz®. This innovative treatment, containing aminolevulinic acid hydrochloride gel, is specifically designed to combat mild to moderate actinic keratoses (AKs) on peripheral body areas. The study marked the end of patient visits, highlighting a progressive journey toward FDA submission targeted for summer 2026.
The Importance of Actinic Keratosis Treatment
Actinic keratosis is a common pre-cancerous skin condition primarily caused by prolonged sun exposure. Left untreated, AKs have the potential to evolve into more severe skin cancers, such as squamous cell carcinoma. By showcasing the safety and efficacy of Ameluz®, this study contributes substantially to enhancing treatment options for patients at risk.
Milestones and Future Aspirations
Dr. Hermann Luebbert, CEO and Chairman of Biofrontera Inc., expressed delight at reaching this significant clinical milestone. He emphasized that the completion of the Phase 1 study is a critical step towards expanding the utilization of Ameluz® for the treatment of AKs across various body areas. This potential label extension not only holds importance for enriching patient care but aligns with Biofrontera's ambition to lead in photodynamic therapy (PDT) within dermatology.
Contributions from Dermatology Experts
Contributing to the Phase 1 study, Dr. Ted Lain, a board-certified dermatologist, conveyed optimism about the prospective benefits of Ameluz® PDT for patients dealing with AKs on areas beyond the face and scalp. His insights reaffirm the necessity for extended treatment options in dermatology, addressing a gap in current facilities.
The Path Forward with Regulatory Approvals
Pending favorable results from this trial, alongside favorable outcomes from the corresponding Phase III studies, Biofrontera aims to submit a supplemental New Drug Application (sNDA) to the FDA by the scheduled summer of 2026. These actions underline Biofrontera's strategic focus on expanding the Ameluz® label, thus transitioning the company into a new era of dermatological treatment possibilities.
About Biofrontera Inc.
Biofrontera Inc. is a biopharmaceutical company based in the U.S., primarily focused on the treatment of dermatological conditions through innovative therapies. The company has successfully commercialized the drug-device combination Ameluz® for the PDT of actinic keratoses, which significantly underpins its mission to address critical healthcare needs. Ongoing clinical trials are set to extend their offerings to include non-melanoma skin cancers and alternative dermatological applications, reflecting a comprehensive approach to patient care.
Frequently Asked Questions
What is Ameluz® used for?
Ameluz® is primarily used for the treatment of mild to moderate actinic keratoses on areas of the body other than the face and scalp.
When is Biofrontera planning to submit for FDA approval?
The company aims to submit a supplemental New Drug Application (sNDA) to the FDA in summer 2026.
What are actinic keratoses?
Actinic keratoses are pre-cancerous skin lesions that can develop due to chronic sun exposure, leading to potential skin cancer if untreated.
Who is involved in the Phase 1 study?
The study involved multiple experts, including Dr. Hermann Luebbert and Dr. Ted Lain, who contributed their dermatological expertise to the project.
What is Biofrontera's corporate focus?
Biofrontera focuses on developing dermatological treatments, particularly through photodynamic therapy (PDT), enhancing care for skin conditions.
